Loading…
Loading…
The decree does not impose a hard local-content mandate — foreign multinationals without Mexican manufacturing can still bid — but it structurally tilts the federal government's single largest pharmaceutical buyer (the IMSS-Bienestar-led consolidated purchase mechanism) toward suppliers with committed physical investment or R&D presence in Mexico. No specific point weighting or percentage threshold has been disclosed publicly yet; that detail is left to the Secretaría de Salud's implementing guidelines, due within 90 days of the 2025-06-02 publication (i.e., by roughly early September 2025). The decree also names the state firm Birmex as the intended logistics hub and anchor state producer for the resulting supply chain buildout.
Severity is set qualitative (3/5) because the mechanism is procurement preference/investment-promotion rather than an outright market-access bar, its bite is deferred to FY2026 evaluation cycles, and the quantitative weighting has not yet been published.
labs, or warehouses face a growing competitive disadvantage in federal consolidated tenders starting with FY2026 purchasing.
footprints by major suppliers ahead of the 2026 evaluation cycle, timed to qualify for the points-and-percentage scheme.
~September 2025) to disclose the actual quantitative weighting — this action should be amended with a magnitude: block once published.
assign to domestic investment vs. price and other criteria?
at over MXN 23 billion) undermine the incentive effect of this decree?
response to this decree?